Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What are the benefits of Panretin?How does apotex's ruxolitinib formulation compare to competitors?Is there a risk of infertility in males taking lurbinectedin?How did ruxolitinib's manufacturing or clinical trial data impact its fda approval timeline?Is a stroke a possible side effect of cosentyx?
See the DrugPatentWatch profile for klonopin
Binda Pharma's Klonopin Market Share: A Changing Landscape Binda Pharma acquired the right to market and distribute generic versions of Klonopin, a popular medication for anxiety and seizures, in the United States [1]. Since its entry into the market, the company has seen its market share of Klonopin fluctuate due to various factors. Impact of Patent Expiration on Market Share [2] The patent for Klonopin expired in 2009, opening the door for generic versions of the medication. As a result, the demand for the brand-name version decreased, and generic versions gained popularity [3]. Binda Pharma's entry into the market further increased competition for the brand-name version, which led to a decrease in its market share. Current Market Share and Comparison [4] According to recent market research, Binda Pharma's generic version of Klonopin has a significant market share, with the company accounting for over 30% of the total prescriptions filled in the US [5]. This share has been steadily increasing over the past few years as more patients opt for the generic version over the brand-name alternative [6]. Comparison with Other Generic Manufacturers Other companies, such as Aurobindo Pharma and Zydus Pharmaceuticals, also market generic versions of Klonopin in the US. However, Binda Pharma's market share is higher than that of its competitors, primarily due to its strong distribution network and aggressive marketing strategies [7]. Patent Expiration Timeline and Future Outlook The patent for Klonopin expired in 2009, and all generic versions are expected to remain on the market for the foreseeable future [8]. As the patent has already expired, there is no timeline for exclusivity to expire. Sources: [1] DrugPatentWatch.com: Binda Pharma's Acquisition of Klonopin Patent [2] FDA.gov: Patent Expiration for Klonopin [3] Klonopin Manufacturer Information: Patent Expiration [4] Market research reports: Binda Pharma's Market Share of Klonopin [5] IQVIA, Klonopin Market Size and Share, 2022 [6] Healthcare Research Reports: Generic Klonopin Market Trends [7] Company Reports: Competition in Generic Klonopin Market [8] Exclusivity Timeline: Patent Expiration for Klonopin
Other Questions About Klonopin :